Meghan Elizabeth Sise, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Kidney Injury | 30 | 2024 | 1967 | 6.010 |
Why?
|
Hepatitis C | 25 | 2023 | 1582 | 5.480 |
Why?
|
Renal Insufficiency, Chronic | 22 | 2024 | 2195 | 4.370 |
Why?
|
Antiviral Agents | 31 | 2023 | 2978 | 4.090 |
Why?
|
Hepatitis C, Chronic | 15 | 2023 | 1027 | 3.600 |
Why?
|
Kidney Failure, Chronic | 14 | 2023 | 2536 | 2.920 |
Why?
|
Nephritis, Interstitial | 7 | 2024 | 156 | 2.790 |
Why?
|
Hepacivirus | 17 | 2023 | 1372 | 2.320 |
Why?
|
Kidney Transplantation | 14 | 2021 | 4246 | 2.000 |
Why?
|
Kidney | 22 | 2023 | 7167 | 1.790 |
Why?
|
Renal Insufficiency | 3 | 2023 | 802 | 1.650 |
Why?
|
Glomerular Filtration Rate | 13 | 2023 | 2167 | 1.640 |
Why?
|
Thyroiditis | 2 | 2021 | 85 | 1.550 |
Why?
|
Lipocalins | 9 | 2012 | 170 | 1.300 |
Why?
|
Acute-Phase Proteins | 9 | 2012 | 262 | 1.270 |
Why?
|
Kidney Diseases | 7 | 2019 | 2145 | 1.190 |
Why?
|
Cryoglobulinemia | 2 | 2018 | 87 | 1.130 |
Why?
|
Proteinuria | 5 | 2023 | 657 | 1.120 |
Why?
|
Benzimidazoles | 4 | 2021 | 848 | 1.100 |
Why?
|
Renal Dialysis | 7 | 2022 | 1780 | 1.050 |
Why?
|
Prednisone | 2 | 2021 | 1567 | 1.030 |
Why?
|
Tissue Donors | 9 | 2023 | 2205 | 0.990 |
Why?
|
Adenosine Monophosphate | 3 | 2021 | 276 | 0.970 |
Why?
|
Creatinine | 11 | 2024 | 1916 | 0.950 |
Why?
|
Glomerulosclerosis, Focal Segmental | 3 | 2017 | 359 | 0.950 |
Why?
|
Alanine | 3 | 2021 | 572 | 0.950 |
Why?
|
Immunotherapy, Adoptive | 3 | 2022 | 1255 | 0.910 |
Why?
|
Aminoisobutyric Acids | 2 | 2020 | 38 | 0.810 |
Why?
|
Nephrology | 2 | 2022 | 260 | 0.790 |
Why?
|
Hyperkalemia | 1 | 2023 | 218 | 0.780 |
Why?
|
Hepatitis B | 3 | 2023 | 695 | 0.780 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 1377 | 0.780 |
Why?
|
Neoplasms | 11 | 2023 | 21596 | 0.760 |
Why?
|
Hypokalemia | 1 | 2021 | 153 | 0.760 |
Why?
|
Graft vs Host Disease | 3 | 2023 | 2951 | 0.740 |
Why?
|
Fluorenes | 2 | 2021 | 159 | 0.740 |
Why?
|
Nephritis | 1 | 2021 | 158 | 0.720 |
Why?
|
Cyclopropanes | 2 | 2020 | 416 | 0.710 |
Why?
|
Leucine | 2 | 2020 | 560 | 0.700 |
Why?
|
Glomerulonephritis | 2 | 2020 | 372 | 0.700 |
Why?
|
Lactams, Macrocyclic | 2 | 2020 | 319 | 0.690 |
Why?
|
Proline | 2 | 2020 | 458 | 0.690 |
Why?
|
Quinoxalines | 2 | 2020 | 288 | 0.690 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 113 | 0.670 |
Why?
|
Donor Selection | 5 | 2021 | 201 | 0.660 |
Why?
|
Hyponatremia | 1 | 2021 | 298 | 0.660 |
Why?
|
Retrospective Studies | 38 | 2024 | 77098 | 0.650 |
Why?
|
Albuminuria | 3 | 2019 | 683 | 0.640 |
Why?
|
Ribavirin | 3 | 2016 | 395 | 0.620 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2023 | 5425 | 0.610 |
Why?
|
Humans | 112 | 2024 | 742088 | 0.600 |
Why?
|
Uridine Monophosphate | 1 | 2017 | 69 | 0.590 |
Why?
|
Proto-Oncogene Proteins | 9 | 2012 | 4553 | 0.580 |
Why?
|
Kidney Neoplasms | 3 | 2022 | 4229 | 0.570 |
Why?
|
Serologic Tests | 1 | 2018 | 374 | 0.570 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2023 | 2524 | 0.510 |
Why?
|
Tissue and Organ Procurement | 2 | 2019 | 890 | 0.490 |
Why?
|
Melanoma | 3 | 2022 | 5462 | 0.460 |
Why?
|
Adrenal Cortex Hormones | 2 | 2022 | 1847 | 0.440 |
Why?
|
RNA, Viral | 2 | 2020 | 2899 | 0.420 |
Why?
|
Virus Diseases | 1 | 2018 | 710 | 0.420 |
Why?
|
Interferon-alpha | 2 | 2015 | 895 | 0.420 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3130 | 0.410 |
Why?
|
Rheumatic Diseases | 1 | 2018 | 590 | 0.410 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3236 | 0.410 |
Why?
|
Sulfonamides | 2 | 2020 | 1932 | 0.400 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 2011 | 80 | 0.400 |
Why?
|
Urethral Obstruction | 1 | 2011 | 56 | 0.400 |
Why?
|
Protease Inhibitors | 1 | 2015 | 790 | 0.390 |
Why?
|
Aged | 33 | 2023 | 162944 | 0.390 |
Why?
|
Middle Aged | 41 | 2024 | 213127 | 0.380 |
Why?
|
Viremia | 4 | 2023 | 735 | 0.380 |
Why?
|
Thrombotic Microangiopathies | 2 | 2023 | 132 | 0.370 |
Why?
|
Male | 49 | 2023 | 349538 | 0.370 |
Why?
|
Pyrazoles | 1 | 2020 | 1970 | 0.350 |
Why?
|
Cause of Death | 1 | 2020 | 3571 | 0.350 |
Why?
|
Oligopeptides | 1 | 2015 | 1176 | 0.350 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2275 | 0.330 |
Why?
|
Female | 48 | 2023 | 379592 | 0.330 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2021 | 2229 | 0.330 |
Why?
|
Survival Analysis | 1 | 2021 | 10248 | 0.330 |
Why?
|
HIV Infections | 3 | 2023 | 16678 | 0.320 |
Why?
|
Hematologic Neoplasms | 1 | 2020 | 1820 | 0.320 |
Why?
|
Drug Therapy, Combination | 6 | 2022 | 6483 | 0.300 |
Why?
|
Cisplatin | 2 | 2024 | 1637 | 0.280 |
Why?
|
Infant, Premature, Diseases | 1 | 2012 | 706 | 0.280 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4823 | 0.280 |
Why?
|
Immunotherapy | 5 | 2021 | 4414 | 0.280 |
Why?
|
Carcinoma, Renal Cell | 1 | 2021 | 3123 | 0.280 |
Why?
|
Urinalysis | 3 | 2017 | 369 | 0.270 |
Why?
|
Skin Neoplasms | 3 | 2020 | 5662 | 0.270 |
Why?
|
Bacteremia | 1 | 2012 | 962 | 0.260 |
Why?
|
Liver Cirrhosis | 6 | 2020 | 1864 | 0.250 |
Why?
|
Positron-Emission Tomography | 2 | 2021 | 6259 | 0.250 |
Why?
|
Treatment Outcome | 15 | 2023 | 62966 | 0.240 |
Why?
|
Hydroxylamines | 1 | 2023 | 40 | 0.230 |
Why?
|
Ribose | 1 | 2023 | 68 | 0.230 |
Why?
|
Adult | 28 | 2024 | 213712 | 0.220 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13655 | 0.220 |
Why?
|
Opioid-Related Disorders | 1 | 2018 | 2062 | 0.220 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2024 | 11695 | 0.220 |
Why?
|
Baclofen | 1 | 2023 | 128 | 0.220 |
Why?
|
Hepatitis B virus | 2 | 2023 | 513 | 0.220 |
Why?
|
Disease Progression | 6 | 2022 | 13256 | 0.210 |
Why?
|
Hypertension, Pulmonary | 1 | 2013 | 1527 | 0.210 |
Why?
|
Digoxin | 1 | 2023 | 250 | 0.210 |
Why?
|
Renal Replacement Therapy | 2 | 2023 | 258 | 0.210 |
Why?
|
Cystatin C | 1 | 2023 | 250 | 0.210 |
Why?
|
Taste Disorders | 1 | 2022 | 41 | 0.200 |
Why?
|
Cohort Studies | 12 | 2024 | 40450 | 0.200 |
Why?
|
Ritonavir | 1 | 2023 | 322 | 0.200 |
Why?
|
Pyrrolidines | 2 | 2020 | 342 | 0.200 |
Why?
|
Lung | 1 | 2020 | 9826 | 0.200 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2023 | 441 | 0.200 |
Why?
|
Sepsis | 2 | 2012 | 2589 | 0.190 |
Why?
|
Micropore Filters | 1 | 2020 | 23 | 0.190 |
Why?
|
Electrolytes | 1 | 2021 | 282 | 0.190 |
Why?
|
BK Virus | 1 | 2021 | 129 | 0.190 |
Why?
|
AIDS-Associated Nephropathy | 2 | 2011 | 35 | 0.190 |
Why?
|
Oximes | 1 | 2022 | 309 | 0.180 |
Why?
|
Carboplatin | 1 | 2023 | 799 | 0.180 |
Why?
|
Vancomycin | 1 | 2023 | 500 | 0.180 |
Why?
|
Sodium | 2 | 2024 | 1627 | 0.180 |
Why?
|
Anti-Inflammatory Agents | 2 | 2020 | 1788 | 0.180 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.180 |
Why?
|
Disease Management | 3 | 2020 | 2450 | 0.180 |
Why?
|
Pyrimidinones | 1 | 2022 | 370 | 0.170 |
Why?
|
Heart Failure | 1 | 2023 | 10856 | 0.170 |
Why?
|
Polyomavirus Infections | 1 | 2021 | 196 | 0.170 |
Why?
|
Anti-HIV Agents | 1 | 2015 | 4250 | 0.170 |
Why?
|
Risk Factors | 13 | 2024 | 72145 | 0.170 |
Why?
|
Pneumonia | 2 | 2022 | 2117 | 0.170 |
Why?
|
Olfaction Disorders | 1 | 2022 | 222 | 0.170 |
Why?
|
Adrenal Gland Diseases | 1 | 2020 | 138 | 0.170 |
Why?
|
Pericardial Effusion | 1 | 2021 | 246 | 0.170 |
Why?
|
Kidney Glomerulus | 1 | 2021 | 697 | 0.170 |
Why?
|
Urogenital Neoplasms | 1 | 2020 | 135 | 0.160 |
Why?
|
Tumor Virus Infections | 1 | 2021 | 451 | 0.160 |
Why?
|
Water-Electrolyte Balance | 1 | 2020 | 346 | 0.160 |
Why?
|
Drug Combinations | 2 | 2020 | 1961 | 0.160 |
Why?
|
Injections, Intravenous | 1 | 2020 | 1420 | 0.150 |
Why?
|
Aged, 80 and over | 9 | 2021 | 57683 | 0.150 |
Why?
|
Amides | 1 | 2020 | 458 | 0.150 |
Why?
|
Gout | 1 | 2024 | 556 | 0.150 |
Why?
|
Myositis | 1 | 2020 | 251 | 0.150 |
Why?
|
Pyridones | 1 | 2022 | 712 | 0.150 |
Why?
|
Infant, Very Low Birth Weight | 2 | 2010 | 406 | 0.150 |
Why?
|
Survival Rate | 3 | 2020 | 12773 | 0.140 |
Why?
|
Anti-Bacterial Agents | 3 | 2020 | 7153 | 0.140 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2020 | 299 | 0.140 |
Why?
|
Biopsy | 3 | 2018 | 6756 | 0.140 |
Why?
|
Prognosis | 6 | 2020 | 29010 | 0.140 |
Why?
|
Paclitaxel | 1 | 2023 | 1707 | 0.130 |
Why?
|
Interleukin-2 | 1 | 2023 | 1887 | 0.130 |
Why?
|
Imidazoles | 1 | 2022 | 1205 | 0.130 |
Why?
|
Incidence | 4 | 2022 | 20928 | 0.130 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4929 | 0.130 |
Why?
|
Patient Care Management | 1 | 2018 | 306 | 0.130 |
Why?
|
Postoperative Complications | 1 | 2017 | 15244 | 0.130 |
Why?
|
Time Factors | 6 | 2021 | 40054 | 0.130 |
Why?
|
Hypothyroidism | 1 | 2020 | 659 | 0.130 |
Why?
|
Nitriles | 1 | 2020 | 952 | 0.130 |
Why?
|
Propensity Score | 1 | 2021 | 1771 | 0.130 |
Why?
|
Proton Pump Inhibitors | 1 | 2019 | 521 | 0.120 |
Why?
|
Comorbidity | 2 | 2020 | 10372 | 0.120 |
Why?
|
Immunologic Factors | 2 | 2021 | 1575 | 0.120 |
Why?
|
Drug Monitoring | 1 | 2020 | 956 | 0.120 |
Why?
|
Pyrazines | 1 | 2020 | 1231 | 0.120 |
Why?
|
Chemokine CXCL9 | 2 | 2024 | 132 | 0.120 |
Why?
|
Radiography, Thoracic | 1 | 2020 | 1265 | 0.110 |
Why?
|
Thiosulfates | 1 | 2013 | 52 | 0.110 |
Why?
|
Educational Status | 1 | 2021 | 2533 | 0.110 |
Why?
|
Acute Disease | 2 | 2024 | 7141 | 0.110 |
Why?
|
Heparin | 1 | 2020 | 1636 | 0.110 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2015 | 713 | 0.110 |
Why?
|
Nephrotic Syndrome | 1 | 2017 | 389 | 0.110 |
Why?
|
Lung Neoplasms | 3 | 2022 | 13019 | 0.110 |
Why?
|
Drug Resistance, Viral | 1 | 2018 | 820 | 0.110 |
Why?
|
Informed Consent | 1 | 2019 | 991 | 0.110 |
Why?
|
Interdisciplinary Communication | 1 | 2018 | 950 | 0.110 |
Why?
|
Myocarditis | 1 | 2020 | 770 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 9941 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 11472 | 0.100 |
Why?
|
Pandemics | 3 | 2022 | 8328 | 0.100 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2022 | 2028 | 0.100 |
Why?
|
Chelating Agents | 1 | 2013 | 380 | 0.100 |
Why?
|
Calciphylaxis | 1 | 2013 | 122 | 0.100 |
Why?
|
Critical Illness | 2 | 2023 | 2665 | 0.100 |
Why?
|
Costs and Cost Analysis | 1 | 2017 | 1679 | 0.100 |
Why?
|
Hypoglycemic Agents | 1 | 2023 | 2866 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10943 | 0.100 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2019 | 2013 | 0.100 |
Why?
|
Survivors | 1 | 2021 | 2286 | 0.100 |
Why?
|
Cardiac Output | 1 | 2013 | 853 | 0.090 |
Why?
|
Recovery of Function | 1 | 2021 | 2924 | 0.090 |
Why?
|
Massachusetts | 2 | 2021 | 8662 | 0.090 |
Why?
|
Autoimmunity | 1 | 2018 | 1348 | 0.090 |
Why?
|
Nephrons | 1 | 2012 | 220 | 0.090 |
Why?
|
Physician's Role | 1 | 2017 | 942 | 0.090 |
Why?
|
Risk Assessment | 3 | 2024 | 23320 | 0.090 |
Why?
|
Logistic Models | 4 | 2021 | 13403 | 0.090 |
Why?
|
Cytokines | 2 | 2023 | 7317 | 0.090 |
Why?
|
Genotype | 3 | 2020 | 12946 | 0.080 |
Why?
|
Anticoagulants | 2 | 2020 | 4595 | 0.080 |
Why?
|
Boston | 1 | 2021 | 9305 | 0.080 |
Why?
|
Pyrimidines | 1 | 2020 | 2933 | 0.080 |
Why?
|
Critical Care | 1 | 2020 | 2640 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3497 | 0.070 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5385 | 0.070 |
Why?
|
Azotemia | 2 | 2020 | 8 | 0.070 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2712 | 0.070 |
Why?
|
United States | 4 | 2022 | 69693 | 0.070 |
Why?
|
Young Adult | 4 | 2020 | 56350 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4029 | 0.060 |
Why?
|
Ultrasonography | 1 | 2017 | 5978 | 0.060 |
Why?
|
Prospective Studies | 6 | 2020 | 53187 | 0.060 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2024 | 85 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5171 | 0.060 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 12958 | 0.060 |
Why?
|
Vitamins | 2 | 2022 | 1608 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7276 | 0.050 |
Why?
|
Odds Ratio | 1 | 2015 | 9846 | 0.050 |
Why?
|
Mitochondria | 1 | 2015 | 3520 | 0.050 |
Why?
|
Bilirubin | 1 | 2023 | 424 | 0.050 |
Why?
|
Prevalence | 2 | 2022 | 15194 | 0.050 |
Why?
|
Early Diagnosis | 2 | 2020 | 1184 | 0.050 |
Why?
|
Endothelium, Vascular | 1 | 2013 | 4455 | 0.050 |
Why?
|
Emergency Service, Hospital | 2 | 2012 | 7645 | 0.050 |
Why?
|
Nephrosis, Lipoid | 1 | 2020 | 51 | 0.050 |
Why?
|
Myoglobin | 1 | 2020 | 160 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2015 | 39004 | 0.050 |
Why?
|
Hypertension | 1 | 2020 | 8455 | 0.040 |
Why?
|
Heart | 1 | 2013 | 4462 | 0.040 |
Why?
|
Factor Xa | 1 | 2020 | 162 | 0.040 |
Why?
|
Glomerulonephritis, Membranous | 1 | 2020 | 86 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2012 | 15056 | 0.040 |
Why?
|
Rhabdomyolysis | 1 | 2020 | 150 | 0.040 |
Why?
|
Equipment Contamination | 1 | 2020 | 183 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2023 | 20086 | 0.040 |
Why?
|
Kidney Tubules, Proximal | 1 | 2020 | 417 | 0.040 |
Why?
|
Uric Acid | 1 | 2024 | 760 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2024 | 15108 | 0.040 |
Why?
|
Equipment Failure Analysis | 1 | 2020 | 867 | 0.040 |
Why?
|
Obesity | 1 | 2020 | 12705 | 0.040 |
Why?
|
Mutation | 1 | 2022 | 29717 | 0.040 |
Why?
|
Ascorbic Acid | 1 | 2020 | 647 | 0.040 |
Why?
|
Adolescent | 4 | 2020 | 85649 | 0.040 |
Why?
|
Hospital Mortality | 2 | 2020 | 5310 | 0.040 |
Why?
|
Transplantation Conditioning | 1 | 2023 | 1597 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2303 | 0.030 |
Why?
|
Blood Coagulation | 1 | 2020 | 1126 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2020 | 1459 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2011 | 21719 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 12071 | 0.030 |
Why?
|
Chronic Disease | 1 | 2009 | 9144 | 0.030 |
Why?
|
Regression Analysis | 2 | 2016 | 6452 | 0.030 |
Why?
|
ROC Curve | 2 | 2011 | 3528 | 0.030 |
Why?
|
Cation Exchange Resins | 1 | 2012 | 21 | 0.030 |
Why?
|
Injections, Intralesional | 1 | 2013 | 276 | 0.030 |
Why?
|
Infection Control | 1 | 2020 | 962 | 0.030 |
Why?
|
North America | 1 | 2016 | 1249 | 0.030 |
Why?
|
Chromatography, Ion Exchange | 1 | 2012 | 305 | 0.030 |
Why?
|
Glucose | 1 | 2024 | 4391 | 0.030 |
Why?
|
Chromatography, Gel | 1 | 2012 | 668 | 0.030 |
Why?
|
Research | 1 | 2020 | 1999 | 0.020 |
Why?
|
Hospitalization | 2 | 2021 | 10232 | 0.020 |
Why?
|
Graft Survival | 1 | 2021 | 3733 | 0.020 |
Why?
|
Forecasting | 1 | 2020 | 2948 | 0.020 |
Why?
|
Cross Infection | 1 | 2020 | 1413 | 0.020 |
Why?
|
Pregnancy | 1 | 2012 | 29087 | 0.020 |
Why?
|
Sensitivity and Specificity | 3 | 2011 | 14720 | 0.020 |
Why?
|
Contrast Media | 1 | 2023 | 5295 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2015 | 1181 | 0.020 |
Why?
|
Inpatients | 1 | 2021 | 2495 | 0.020 |
Why?
|
Europe | 1 | 2016 | 3339 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15530 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2011 | 683 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2023 | 13029 | 0.020 |
Why?
|
New York City | 1 | 2010 | 706 | 0.020 |
Why?
|
Remission Induction | 1 | 2013 | 2384 | 0.020 |
Why?
|
Atrophy | 1 | 2012 | 1576 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8621 | 0.020 |
Why?
|
Length of Stay | 1 | 2020 | 6294 | 0.020 |
Why?
|
Viral Load | 1 | 2015 | 3292 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3510 | 0.020 |
Why?
|
New York | 1 | 2008 | 886 | 0.020 |
Why?
|
Fibrosis | 1 | 2012 | 2026 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3862 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2012 | 2203 | 0.020 |
Why?
|
Blotting, Western | 1 | 2012 | 5180 | 0.020 |
Why?
|
Mass Screening | 1 | 2020 | 5238 | 0.020 |
Why?
|
Reference Values | 1 | 2009 | 4982 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12242 | 0.010 |
Why?
|
Gestational Age | 1 | 2010 | 3490 | 0.010 |
Why?
|
Up-Regulation | 1 | 2010 | 4211 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 7716 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2016 | 13921 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2010 | 25575 | 0.010 |
Why?
|
Mice | 2 | 2021 | 81045 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2009 | 9735 | 0.010 |
Why?
|
Sex Factors | 1 | 2009 | 10392 | 0.010 |
Why?
|
Models, Biological | 1 | 2012 | 9581 | 0.010 |
Why?
|
Animals | 2 | 2021 | 168561 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2012 | 17400 | 0.010 |
Why?
|